Back Pain News and Research

Latest Back Pain News and Research

FDA approves Lysteda for treating menorrhagia

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, announced today that Lysteda(TM) (tranexamic acid) oral tablets has received U.S. Food and Drug Administration (FDA) approval for treatment of women suffering from cyclic heavy menstrual bleeding (HMB), also known as menorrhagia.

16 Nov 2009

Spine Care Institute established by Hospital for Special Surgery

Hospital for Special Surgery today announced the establishment of one of the most comprehensive centers of excellence in the country for the treatment of all nonoperative and operative spine disorders.

16 Nov 2009

Doctors face image problems; patients deal with shortages, are urged to question care

Doctors must not only face the fading image of primary care providers, but also physician shortage issues. Meanwhile, some experts suggest patients consider saying "no" to their doctor to control health care costs.

13 Nov 2009

SpinalMotion submits Kineflex lumbar artificial disc PMA to FDA

SpinalMotion, developer of the investigational Kineflex® lumbar and Kineflex/C® cervical disc implants for treating patients with degenerative disc disease (DDD), today reported that it has submitted the Pre-Market Approval (PMA) to FDA for the Kineflex lumbar artificial disc

13 Nov 2009

Nutra Pharma to market its OTC pain reliever in Brazil and Colombia, begins the drug registration process

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it plans to begin the drug registration process in Brazil and Colombia for its over-the-counter (OTC) pain reliever. The company is currently marketing a similar drug in the United States under the brand name Cobroxin for the treatment of moderate to severe (Stage 2) chronic pain.

13 Nov 2009

Abbott signs agreement to acquire global rights to PanGenetics BV's PG110

Abbott announced today a definitive agreement to acquire the global rights to PanGenetics BV's PG110 fully humanized antibody to Nerve Growth Factor (NGF), expanding the company's pain care portfolio and leveraging its expertise in biologics. PG110 is a novel biologic in Phase I clinical trial development that targets NGF for the treatment of chronic pain.

13 Nov 2009

Abbott to acquire the global rights to PanGenetics' new therapeutic for treatment of chronic pain

PanGenetics, an antibody development company which is developing PG110, a humanized antibody to Nerve Growth Factor (NGF), today announced it has entered into an agreement with Abbott under which Abbott will acquire the global rights to this novel biologic. PG110 is currently in a Phase 1 clinical trial in patients with osteoarthritis and represents a promising new therapeutic for the treatment of chronic pain.

13 Nov 2009

Adolor commences clinical testing of its oral mu opioid receptor antagonist

Adolor Corporation today announced the initiation of clinical testing of ADL7445, its proprietary, oral mu opioid receptor antagonist for the treatment of Opioid Bowel Dysfunction (OBD). The Phase 1, single ascending dose trial in healthy volunteers will assess safety and tolerability of the compound and will be followed by a multiple ascending dose study in early 2010.

13 Nov 2009

A discreet option for pain relief in the workplace

Employers say that back pain-related problems account for over 100 million lost workdays a year. In a cutthroat economy with unemployment at a record high, this is especially disconcerting news. Employees cannot afford to risk losing their jobs to other candidates while stuck home in bed recuperating. With 80% of Americans experiencing back pain in their lifetime, back issues have serious implications on job security and can negatively affect even the most dedicated employee’s performance abilities and job attendance.

12 Nov 2009

Osteotech highlights Magnifuse bone grafting products at NASS Annual Meeting

Osteotech, Inc., a leader in the emerging field of biologic products for regenerative healing, today announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products for different spine therapy areas at the North American Spine Society (NASS) 2009 Annual Meeting, taking place November 10th through 14th in San Francisco, California. To date MagniFuse has been used in 40 spinal surgeries in the United States

11 Nov 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Military personnel with back pain unlikely to return to duty after treatment

Military personnel evacuated out of Iraq and Afghanistan because of back pain are unlikely to return to the line of duty regardless of the treatment they receive, according to research led by a Johns Hopkins pain management specialist.

9 Nov 2009

Health education on ID and stability balls, an opportunity for healthier life

An Indiana University study involving adults with intellectual disabilities found that the adults increased their personal health knowledge after taking a semi-weekly class for four weeks.

9 Nov 2009

Facet Solutions announces Archus Orthopedics acquisition

Facet Solutions, Inc. announced today that it has acquired all of the assets of Archus Orthopedics. The acquisition creates an undisputed leadership position in product offerings, intellectual property and clinical experience in posterior motion preservation. "This is a win for patients suffering from lumbar spinal stenosis," stated Facet Solutions' President & CEO, Geoff Pardo. "This consolidation further strengthens Facet Solutions' position in lumbar spine motion preservation surgery, which is the fastest growing sector of the surgical spine marketplace."

6 Nov 2009

Yoga may be more effective for reducing chronic low back pain, say researchers

Researchers from Boston University School of Medicine (BUSM) and Boston Medical Center found that yoga may be more effective than standard treatment for reducing chronic low back pain in minority populations. This study appears in the November issue of Alternative Therapies in Health and Medicine.

5 Nov 2009

Spinal Modulation completes its $27.4 million Series C financing

Spinal Modulation, Inc. announced today the completion of its $27.4 million Series C financing. Johnson & Johnson Development Corporation (JJDC) joined existing major investors including DeNovo Ventures, ePlanet/DFJ, Kleiner Perkins Caufield & Byers, and MedVenture Associates in this financing. DFJ/InCube Ventures and Raffles Venture Partners are additional new investors.

4 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Dr. Chao Herbal Drink Line releases two all-natural, vegan beverages

The Dr. Chao Herbal Drink Line released two all-natural, vegan beverages to enhance sexual health and combat premenstrual symptoms. The new Adult and Lady drinks have no sugar, artificial sweeteners or preservatives, glutens, and caffeine, do not require costly prescriptions and have health benefits derived from the recipes of a 19th-century Chinese herbalist.

30 Oct 2009

Patient self-referral to physiotherapy proven to be safe, and results in better health outcomes

Today in Washington, DC, physiotherapists from around the world heard that direct patient access and self-referral to physiotherapy improves public health. Patient self-referral and direct access is proven to be safe, and results in better health outcomes, more timely care, higher patient satisfaction, and lower costs.

28 Oct 2009

Discovery of AVM can relieve pain due to chronic back pain and neurologic deficits

The discovery of a multi-level arteriovenous malformation (AVM) in the thoracic epidural space can now bring relief to potentially thousands of suffers of chronic thoracic pain and progressive myelopothy. Identified as thoracic epidural arteriovenous malformation (T.E.A.M.), this particular AMV primarily affects younger women ages 20 to 40.

27 Oct 2009